Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10828787 | PMC |
| http://dx.doi.org/10.3324/haematol.2023.282812 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lower baseline scores best predict achievement of the minimal clinically important difference after hip arthroscopy: A machine learning analysis from the Femoroacetabular Impingement RandomiSed Controlled Trial and embedded prospective cohort.
Knee Surg Sports Traumatol Arthrosc
September 2025
Department of Surgery, Division of Orthopaedic Surgery, McMaster University, Hamilton, Ontario, Canada.
Purpose: This analysis evaluated whether logistic regression and machine learning models could predict achievement of the minimal clinically important difference (MCID) for the International Hip Outcome Tool (iHOT-12) and Hip Outcome Score (HOS) at 6 and 12 months following hip arthroscopy.
Methods: Data from the multicenter Femoroacetabular Impingement RandomiSed controlled Trial and its embedded prospective cohort were used. A total of 309 patients (mean ± SD age 34.
The Utility of Cervical Vertebral Maturation Method for Staging Skeletal Growth and Curve Progression in Patients with Adolescent Idiopathic Scoliosis.
JB JS Open Access
September 2025
Department of Orthopaedics and Traumatology, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.
Background: Cervical vertebral maturation (CVM) is a skeletal maturity method that can be assessed routinely on whole spine radiographs to minimize radiation exposure. Originally used in orthodontics, its role in staging adolescent growth spurt and curve progression in adolescent idiopathic scoliosis (AIS) remains unclear. The aim of this study was to investigate growth rates across CVM stages, its cutoff for indicating peak growth (PG) versus growth cessation (GC), and its relationship with coronal curve progression.
View Article and Find Full Text PDFMinimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.
Blood Neoplasia
November 2025
Section of Hematology/Oncology, The University of Chicago, Chicago, IL.
Modern multiple myeloma treatment enables deep and sustained responses, necessitating assessment of minimal residual disease (MRD) in the bone marrow to refine response categorization. Recently, mass spectrometry (MS)-based methods have emerged as highly sensitive tools for measuring MRD in the peripheral blood. However, the role specific MS techniques play in response categorization has yet to be established.
View Article and Find Full Text PDFTargeting TAMs & CAFs in melanoma: New approaches to tumor microenvironment therapy.
Oncol Res
September 2025
Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, 420008, Russia.
Melanoma is a malignant neoplasm with a high propensity to metastasize, arising from melanocytes and contributing significantly to global morbidity and mortality. Despite the demonstrated efficacy of many immunotherapy approaches, these methods rely on direct destruction of tumor cells with minimal impact on the aggregate of nearby non-tumor cells, the extracellular matrix, and blood vessels that form the tumor microenvironment (TME). The TME is known to be heterogeneous and dynamic, exerting both antitumor and pro-tumor effects depending on the specific features and stage of carcinogenesis.
View Article and Find Full Text PDFThe impact of immunotherapy on the prognosis of small cell carcinoma of the esophagus: a propensity score-matched analysis of a retrospective study.
Front Immunol
September 2025
Department of Radiation Oncology, Affiliated Hospital of Shandong University of Chinese Medicine, Jinan, China.
Objective: Small cell carcinoma of the esophagus (SCCE) is a rare neuroendocrine malignancy with no standardized treatment regimen. This study aims to evaluate the impact of immunotherapy on the prognostic survival outcomes of patients with SCCE.
Methods: A retrospective analysis was conducted on 83 SCCE patients treated at the Provincial Hospital of Shandong First Medical University and the Cancer Hospital of Shandong First Medical University from January 2020 to June 2024.